Smoldering Multiple Myeloma — Trials

Smoldering Multiple Myeloma — Trials · CancerIndex

Clinical trials

Registered studies

85 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 34
Recruiting: 13
Ph III recruiting: 1
Growth YoY: —
Industry share: 9%
Top sponsor: Dana-Farber Cancer Institute
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06183489	Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma(ERASMM)	active not recruiting	Phase 2	50	European Myeloma Network B.V.NETWORK	4	Sep 2, 2026	clinicaltrials
NCT05014646	Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients	active not recruiting	Phase 2	27	City of Hope Medical CenterOTHER	1	Apr 30, 2026